Expert advisors to guide the selection and execution of cognitive measurement across all indications and phases of clinical development.
With access to thousands of cognitive data profiles generated in a wide variety of study populations, and pharmacological interventions spanning a range of mechanisms of action, Cogstate can provide robust interpretation of study results supportive of product efficacy, safety and differentiating claims.
Our expert scientists are actively engaged with leading academics around the world to use the Cogstate expertise and systems to solve some of today’s most pressing issues in the understanding of cognitive decline associated with neurodegenerative diseases such as Alzheimer’s disease. Other areas of significant scientific contributions include depression, schizophrenia, multiple sclerosis, oncology, HIV dementia, autism and many others.
Professor Paul Maruff is one of the founders of Cogstate. He is a neuropsychologist with expertise in the identification and measurement of subtle behavioural and cognitive dysfunction. Paul’s research integrates conventional and computerized neuropsychological testing with cognitive neuroscientific methods.
Dr. Siemers’ experience in clinical trials of neurodegenerative disease spans over 25 years, with a research focus on the use of biomarkers in investigational drug research, the development of trial designs that fully characterize the effects of investigational drugs on chronic diseases, and more specifically, the development of strategies for treating individuals before the onset of symptoms of neurodegenerative diseases.
Dr. Edgar is an experienced leader in cognitive assessment and clinical endpoint strategy who provides expert guidance to Cogstate’s pharmaceutical customers throughout all stages of trial conduct, from study design and test selection through final analysis. Dr. Edgar is also a key advisor to Cogstate’s commercial and product teams for the development of new technologies.
Pam Ventola, PhD is Senior Science Director at Cogstate and Assistant Professor at the Yale Child Study Center. She leads Cogstate’s pediatric and rare diseases portfolio, providing customers with strategic oversight and guidance in all stages of study planning and execution – from endpoint selection to final statistical analysis.
Jason A. Cromer, PhD, Director of Clinical Science at Cogstate, is responsible for scientific operations of all clinical trials that use Cogstate computerized tests. Dr. Cromer earned his BS in Computer Science from Lafayette College and his PhD in Biomedical Science with a specialty in Neuroscience from the University of Connecticut Health Center.
Edward I. Bartolic, PhD, is a clinical neuropsychologist with 20 years experience. He has held various scientific positions with contract research organizations, including Director of CNS Research and Scientific Director for Rater Training Services department at i3 Research and Director of Clinical Assessment Technologies at Worldwide Clinical Trials.
Lisle Kingery, PhD is a licensed clinical psychologist with 20 years’ clinical and research experience in clinical psychology and neuropsychology. He completed a PhD in clinical psychology at the University of Maine, an internship at the University of Michigan, and a postdoctoral fellowship at Johns Hopkins University.
Robert McCue, PsyD, MSCP is a licensed psychologist with 20 years’ experience in neuropsychology and 10 years’ experience teaching assessment and psychopharmacology courses. He completed a PsyD in clinical psychology at the Nova Southeastern University, an internship at the University of Miami, and a master’s degree in clinical psychopharmacology.
Dr. Robyn Powers completed her PhD in Clinical Neuropsychology from the City University of New York (CUNY), as well as a Master’s degree at Columbia University. She has worked clinically with diverse populations including pediatric, elderly, oncology, rehabilitative health, and epilepsy.
Ernest Fung, PsyD, ABPP is a clinical and forensic neuropsychologist, with expertise covering a broad spectrum of CNS indications, from traumatic brain injury to neurodegenerative disorders. He is board certified in clinical neuropsychology by the American Board of Professional Psychology.
Svenja Wacker, PhD is a bilingual (German/English), licensed clinical neuropsychologist with expertise in global clinical trial management and consultation, as well as extensive experience in hospital-based rehabilitation neuropsychology, neuropsychological assessment and intervention, program development, and medical staff training. She serves as Science Director on Cogstate’s Business Development team.
Cogstate’s computerized tests are used to assess cognition in hundreds of clinical trials worldwide. Each Cogstate test provides rapid, reliable, highly sensitive and valid measurement of distinct cognitive functions.
Cogstate’s dynamic relationships among science, operations and technology enable us to deliver exemplary service and novel technologies for the support of scale management, rater training, eCOA and central monitoring programs.
Please fill out the form to get in touch